Le Lézard
Classified in: Health, Business
Subject: ERN

Tocagen Reports Fourth Quarter and Full Year 2017 Financial and Business Results



SAN DIEGO, March 8, 2018 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2017.

Tocagen Inc. (PRNewsfoto/Tocagen Inc.)

"We had an excellent finish to the year with the acceleration of Toca 511 & Toca FC development into a pivotal Phase 3 trial and the presentation of updated data demonstrating continued favorable safety and long-term durable responses in patients with recurrent high-grade glioma," said Marty Duvall, chief executive officer of Tocagen. "With the closing of our upsized public offering in 2017 and enrollment in our Phase 3 trial remaining on track to complete in 2018, we believe we are well positioned to advance our lead program and platform technology in the year ahead."

Fourth Quarter 2017 and Recent Progress

2018 Milestones

Fourth Quarter 2017 Financial Results

Research and Development (R&D) Expenses: R&D expenses were $8.3 million for the quarter ended December 31, 2017, compared to $6.6 million for the quarter ended December 31, 2016. The R&D expenses in both periods were primarily driven by costs to support the Toca 5 trial and to support the manufacturing of drug product. The increase in 2017 reflects primarily higher personnel costs as compared to the same period in 2016.

General and Administrative (G&A) Expenses: G&A expenses were $2.4 million for the quarter ended December 31, 2017, compared to $1.4 million for the quarter ended December 31, 2016. The increase in G&A expenses was primarily due to higher costs to support increased operations activity and costs associated with being a public company during the fourth quarter of 2017, including a $0.5 million increase in stock-based compensation compared to the same period in the prior year.

Net Loss: Net loss was $10.8 million, or $0.55 per common share (basic and diluted), for the quarter ended December 31, 2017, compared to a net loss of $8.4 million, or $3.83 per common share (basic and diluted), for the quarter ended December 31, 2016. The 2017 calculation is based on 19.8 million average common shares outstanding for the fourth quarter of 2017, compared to 2.2 million average common shares outstanding for the fourth quarter of 2016.

2017 Twelve-Month Results

R&D Expenses: R&D expenses were $29.1 million for the 12 months ended December 31, 2017, compared to $27.2 million for the 12 months ended December 31, 2016. The increase in R&D expenses primarily reflects increased personnel costs to support the Toca 5 clinical trial.

G&A Expenses: G&A expenses were $8.6 million for the 12 months ended December 31, 2017, compared to $4.5 million for the 12 months ended December 31, 2016, with the increase primarily driven by higher costs to support increased operations activity and costs associated with being a public company, including a $1.9 million increase in stock-based compensation compared to the same period in the prior year.

Net Loss: Net loss was $38.9 million, or $2.66 per common share (basic and diluted), for the 12 months ended December 31, 2017, compared to a net loss of $33.5 million, or $15.22 per common share (basic and diluted), for the 12 months ended December 31, 2016. The 2017 calculation is based on 14.6 million average common shares outstanding for the 12 months ended December 31, 2017, compared to 2.2 million average shares outstanding for the same period in the prior year.

Cash Position and Guidance

Cash, cash equivalents and marketable securities were $88.7 million at December 31, 2017 compared to $31.2 million at December 31, 2016. In April 2017, Tocagen raised $97.8 million of gross proceeds in an initial public offering (IPO). Based on current operating plans, Tocagen estimates the total cash used in 2018 to fund operations, capital expenditures and debt amortization will not exceed $50 million.

About Toca 511 & Toca FC

Tocagen's lead product candidate is a two-part cancer-selective immunotherapy comprised of an investigational biologic, Toca 511, and an investigational small molecule, Toca FC. Toca 511 is a retroviral replicating vector (RRV) that selectively infects cancer cells and delivers a gene for the enzyme, cytosine deaminase (CD). Through this targeted delivery, only infected cancer cells carry the CD gene and produce CD. Toca FC is an orally administered prodrug, 5-fluorocytosine (5-FC), which is converted into an anti-cancer drug, 5-fluorouracil (5-FU), when it encounters CD. 5-FU kills cancer cells and immune-suppressive myeloid cells resulting in anti-cancer immune activation and subsequent tumor killing.

About Tocagen

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer. Tocagen's lead investigational product candidate, Toca 511 & Toca FC, is under evaluation in a pivotal Phase 3 trial for recurrent high-grade glioma (HGG), a disease with significant unmet medical need. The U.S. Food and Drug Administration (FDA) has granted Toca 511 & Toca FC Breakthrough Therapy Designation for the treatment of recurrent HGG and the European Medicines Agency (EMA) has granted Toca 511 PRIME (PRIority MEdicines) for the treatment of HGG. For more information about Tocagen, visit www.tocagen.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our business plans and objectives, expectations regarding the timing and success of our clinical trials and planned clinical trials, activities related to development of our current and future product candidates in additional indications and our plan to update our regulatory plans. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost and timing of our product candidate development activities and planned clinical trials; our ability to execute on our strategy; regulatory developments in the United States and foreign countries; and our estimates regarding expenses, future revenue and capital requirements. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Tocagen's filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Tocagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

TOCAGEN INC.

CONDENSED BALANCE SHEETS

(in thousands)




December 31,



December 31,



2017



2016



(unaudited)





Cash, cash equivalents and marketable securities


$

88,725



$

31,245

Prepaid expenses and other assets



3,348




4,106

Total assets


$

92,073



$

35,351

Current liabilities



17,330




14,382

Notes payable and other long-term liabilities



3,661




10,435

Convertible promissory notes payable and subscription liability



-




3,538

Convertible preferred stock



-




131,413

Total stockholders' equity (deficit)



71,082




(124,417)

Total liabilities, convertible preferred stock and stockholders' equity (deficit)


$

92,073



$

35,351

 

TOCAGEN INC.

CONDENSED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)




Three Months Ended


Years Ended



December 31,


December 31,



2017


2016


2017


2016



(unaudited)


(unaudited)

License revenue


$

10


$

11


$

41


$

49

Operating expenses:













Research and development



8,294



6,633



29,113



27,218

General and administrative



2,403



1,352



8,557



4,522

Total operating expenses



10,697



7,985



37,670



31,740

Loss from operations



(10,687)



(7,974)



(37,629)



(31,691)

Other expense, net



(150)



(456)



(1,300)



(1,787)

Net loss


$

(10,837)


$

(8,430)


$

(38,929)


$

(33,478)

Net loss per common share, basic and diluted


$

(0.55)


$

(3.83)


$

(2.66)


$

(15.22)

Weighted-average number of common shares outstanding, basic and diluted



19,831,413



2,202,493



14,607,909



2,199,964

 

Media Contact:
Monica May
Canale Communications
(619) 849-5383
monica@canalecomm.com

Investor Contact:
Elizabeth Broder
The Trout Group
(646) 378-2945
ebroder@troutgroup.com

 

SOURCE Tocagen Inc.


These press releases may also interest you

at 00:00
Autoinsurancequotesave.com has released a new blog post that informs customers what questions to ask car insurance agents when negotiating. This website also provides free car insurance quotes online! Car insurance agents are professionals who...

23 jun 2018
One month after opening its taproom, Athletic Brewing Company is proud to announce that it has partnered with Star Distributors to launch their two flagship non-alcoholic offerings, Upside Dawn Golden Ale and Run Wild IPA, state-wide in Connecticut....

23 jun 2018
Onlinequotesautoinsurance.com has released a new blog post where it explains what questions should be asked car insurance agents during negotiations. Car insurance agents are salesmen and their duty is to connect the potential customer to their...

23 jun 2018
Employer wellness programs that combine laboratory and biometric screening with digital behavioral counseling can significantly reduce employees' risk of developing chronic conditions such as diabetes and cardiovascular disease, according to new...

23 jun 2018
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ADT Inc. pursuant and/or traceable to the registration statement and prospectus (the "Registration...

23 jun 2018
Please be advised that MP T.J. Harvey, will announce road infrastructure funding for the Tobique First Nation, on behalf of the Honourable Jane Philpott, Minister of Indigenous Services. A brief media availability will take place following the...




News published on 8 march 2018 at 16:05 and distributed by: